Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasms 2Thoracic Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Lymphoma, Large B-Cell, Diffuse 1Locally Advanced or Metastatic Solid Tumors 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1

Interventions

entinostat 3pembrolizumab 2osimertinib 2Gefitinib 2Erlotinib Hydrochloride 2sotorasib 1pralsetinib 1ficlatuzumab 1exemestane 1efineptakin alfa 1durvalumab 1cobimetinib 1camrelizumab 1Tyrosine Kinase Inhibitors 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Proton Therapy 1Pemetrexed 1Magnetic Resonance Imaging 1Intubation 1Injections, Epidural 1Electrocardiography 1Echocardiography 1Dasatinib 1Carboplatin 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thoracic Neoplasms × efineptakin alfa × Clear all
NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NeoImmuneTech

Phase 1/2 Completed
215 enrolled 30 charts
BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡